Mark Johns, MD
Hematology & Oncology · Cincinnati, OHNPI 1407040884
Payments from drug & device makers
Across 1,888 payments — averaging $529.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biontech SE$270K
- F. Hoffmann-la Roche AG$214K
- Genentech, Inc.$179K
- Eisai Inc.$157K
- E.r. Squibb & Sons, L.L.C.$65K
- Merck$40K
- plus $74K from 23 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biontech SE | 110 | $270,112 |
| F. Hoffmann-la Roche AG | 26 | $214,294 |
| Genentech, Inc. | 53 | $179,443 |
| Eisai Inc. | 1,562 | $156,670 |
| E.r. Squibb & Sons, L.L.C. | 5 | $64,739 |
| Merck | 9 | $40,090 |
| AstraZeneca | 7 | $20,553 |
| AbbVie | 3 | $19,554 |
| Incyte Corporation | 23 | $16,094 |
| Boehringer Ingelheim International GmbH | 7 | $8,156 |
| Pfizer | 21 | $3,588 |
| Ipsen Biopharmaceuticals, Inc | 18 | $1,718 |
| Seagen Inc. | 4 | $1,700 |
| Novartis | 24 | $1,467 |
| Janssen Scientific Affairs, LLC | 1 | $147 |
| Astellas Pharma US Inc | 1 | $124 |
| Progenics Pharmaceuticals, Inc. | 1 | $121 |
| Bioprotect Medical, Inc. | 1 | $117 |
| Johnson & Johnson | 2 | $116 |
| Myriad Genetic Laboratories, Inc. | 1 | $109 |
| Foundation Medicine, Inc. | 1 | $80 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $30 |
| Sun Pharmaceutical Industries Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $22 |
| Regeneron Healthcare Solutions, Inc. | 1 | $22 |
| AVEO Pharmaceuticals, Inc. | 1 | $20 |
| Tactile Systems Technology Inc | 1 | $14 |
| Gilead | 1 | $12 |
| Epizyme, Inc. | 1 | $12 |
How this compares
$999,146 in reported general payments places this provider in the 90th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other hematology & oncology in Cincinnati
- Trisha Wise-DraperCincinnati$9.8M
- Davendra SohalCincinnati$8.6M
- David WaterhouseCincinnati$5.7M
- Patrick WardCincinnati$3.8M
- James EssellCincinnati$3.7M
- Edward FaberCincinnati$2.3M
- Omar AlkharabshehCincinnati$1.2M
- Alexander StarodubCincinnati$1.1M
- Jason JonesCincinnati$948K
- Shuchi GulatiCincinnati$792K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.